http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Lee, Eun-Sil,Kim, Hwan-Mook,Lee, Sung-Dong,Lee, Kwang-Seung,Park, Song-Kyu,Lee, Chang-Woo,Lee, Ki-Ho,Lee, Ki-Hoon,Lee, Jun-Soo,Hwang, Woo-Ik,In, Man-Jin,Kim, Dong-Chung The Korean Society for Applied Biological Chemistr 2010 Applied Biological Chemistry (Appl Biol Chem) Vol.53 No.3
A lipid-soluble ginseng extract possesses an anticancer activity against advanced human lung tumors in an established murine xenograft model without any sign of toxicity. The extract also shows a potent anti-proliferative activity against human cancer cell lines, leading to expansion of its preclinical applications to specific human tumor types.
Eun Sil Lee,Hwan Mook Kim,Sung Dong Lee,Kwang Seung Lee,Song Kyu Park,Chang Woo Lee,Ki Ho Lee,Ki Hoon Lee,Jun Soo Lee,Woo Ik Hwang,Man Jin In,Dong Chung Kim 한국응용생명화학회 2010 Journal of Applied Biological Chemistry (J. Appl. Vol.53 No.3
A lipid-soluble ginseng extract possesses an anticancer activity against advanced human lung tumors in an established murine xenograft model without any sign of toxicity. The extract also shows a potent anti-proliferative activity against human cancer cell
Lee, Young Sook,Paek, Kyung Shin,Kang, Eun Sil,Jang, Han-su,Kim, Hyo Jung,Kang, Young Jin,Kim, Jin-Hoi,Lee, Hoon Taek,Lee, Jae Heun,Chang, Ki Churl,Nishinaka, Toru,Seo, Han Geuk Elsevier 2005 The international journal of biochemistry & cell b Vol.37 No.11
<P><B>Abstract</B></P><P>To elucidate the molecular mechanisms underlying the up-regulation of aldose reductase observed in many cancer cells, we investigated the signal transduction pathways mediating induction of aldose reductase gene expression by 12-<I>O</I>-tetradecanoylphorbol-13-acetate, a potent tumor promoter. A maximum of four-fold induction in aldose reductase mRNA was demonstrated in HeLa cells treated with 12-<I>O</I>-tetradecanoylphorbol-13-acetate. The increased level of aldose reductase transcript was accompanied by the elevated level of enzyme activity, and completely abolished in the presence of actinomycin D. Inhibitors of protein kinase C, bisindolylmaleimide I and calphostin C, as well as inhibitors of tyrosine kinase, genistein and tyrphostin A23, significantly attenuated 12-<I>O</I>-tetradecanoylphorbol-13-acetate-induced increase in aldose reductase mRNA. Blockade of the p38 mitogen-activated protein kinase pathway by SB203580 also suppressed 12-<I>O</I>-tetradecanoylphorbol-13-acetate-induced aldose reductase expression. The promoter activity of aldose reductase gene was significantly augmented in the cells treated with 12-<I>O</I>-tetradecanoylphorbol-13-acetate, but attenuated in the presence of bisindolylmaleimide I, tyrphostin A23 or SB203580. Pyrrolidinedithiocarbamate, a nuclear factor κB inhibitor, dose-dependently suppressed 12-<I>O</I>-tetradecanoylphorbol-13-acetate-induced increase in aldose reductase mRNA. 12-<I>O</I>-tetradecanoylphorbol-13-acetate augmented the DNA binding activity of nuclear factor κB and nuclear factor κB-dependent gene transcription, and these effects were attenuated by bisindolylmaleimide I or tyrphostin A23, but not by SB203580. Taken together, activation of protein kinase C and tyrosine kinase by 12-<I>O</I>-tetradecanoylphorbol-13-acetate elicits increased promoter activity of aldose reductase gene via nuclear factor κB. A p38 mitogen-activated protein kinase pathway, distinct from the tyrosine kinase pathway, may also take part in 12-<I>O</I>-tetradecanoylphorbol-13-acetate-induced increase in aldose reductase gene expression.</P>
Lee Soon Min,Lee Jin A,Chung Sung-Hoon,Lee Jang Hoon,Shim Jae Won,Lim Jae Woo,Kim Chang-Ryul,Chang Yun Sil 대한의학회 2023 Journal of Korean medical science Vol.38 No.49
Background: Infants with congenital anomalies of the digestive system and abdominal wall defects requiring surgery are at risk of growth and developmental delays. The aim of this study was to analyze long-term growth and developmental outcomes for infants with congenital anomalies of the digestive system and abdominal wall defects who underwent surgery in Korea. Methods: We extracted data from the Korean National Health Insurance Service database for the years 2013–2019. Major congenital anomalies were defined according to the International Classification of Diseases-10 and surgery insurance claim codes. The χ2 test and the CochranArmitage trend test were performed for data analysis. Results: A total of 4,574 infants with major congenital anomalies in the digestive system and abodminal wall defects, who had undergone surgey, were reviewed. Anorectal obstruction/ stenosis was the most prevalent anomaly (4.9 per 10,000 live births). The prevalence of congenital anomalies of the digestive system was 15.5 per 10,000 live births, and that of abdominal wall defects was 1.5 per 10,000 live births. Seven percent of infants with congenital anomalies in the digestive system died, of which those with diaphragmatic hernia had the highest mortality rate (18.8%). Among 12,336 examinations at 6, 12, 24, 36, 48, 60, and 72 months of age, 16.7% showed a weight below the 10th percentile, 15.8% had a height below the 10th percentile, and 13.2% had a head circumference below the 10th percentile. Abnormal developmental screening results were observed in 23.0% of infants. Infants with esophageal atresia with/without tracheoesophageal fistula most often had poor growth and development. Delayed development and cerebral palsy were observed in 490 (10.7%) and 130 (2.8%) infants respectively. Comparing the results of infants born in 2013 between their 24- and 72-month health examinations, the proportions of infants with poor height and head circumference growth increased by 6.5% and 5.3%, respectively, whereas those with poor weight growth and abnormal developmental results did not markedly change between the two examinations. Conclusion: Infants with congenital anomalies of the digestive system and abdominal wall defects exhibit poor growth and developmental outcomes until 72 months of age. Close monitoring and careful consideration of their growth and development after discharge are required.
HSP25 inhibits radiation-induced apoptosis through reduction of PKCδ-mediated ROS production
Lee, Yoon-Jin,Lee, Dae-Hoon,Cho, Chul-Koo,Chung, Hee-Yong,Bae, Sangwoo,Jhon, Gil-Ja,Soh, Jae-Won,Jeoung, Doo-Il,Lee, Su-Jae,Lee, Yun-Sil Nature Publishing Group 2005 Oncogene Vol.24 No.23
Since radiation-induced caspase-dependent apoptosis and ROS generation were partially prevented by HSP25 overexpression, similar to the treatment of control cells with antioxidant agents such as DPI and tiron, questions arise whether radiation-mediated ROS generation contributes to the apoptotic cell death, and also whether HSP25 overexpression can reduce ROS mediated apoptotic cell death. In the present study, radiation-induced cytochrome c release from mitochondria and activation of caspases accompanied by a decrease of mitochondrial membrane potential in Jurkat T cells were shown to be inhibited by mitochondrial complex I inhibitor rotenone, suggesting that mitochondrial ROS might be important in radiation-induced caspase-dependent apoptosis. When HSP25 was overexpressed, effects similar to the treatment of cells with the antioxidants were obtained, indicating that HSP25 suppressed radiation-induced mitochondrial alteration that resulted in apoptosis. Furthermore, activation of p38 MAP kinase by radiation was associated with radiation-induced cell death and ROS production and PKCδ was an upstream molecule for p38 MAP kinase activation, ROS generation and subsequent caspase-dependent apoptotic events. However, in the HSP25 overexpressed cells, the above-described effects were blocked. In fact, radiation-induced membrane translocation of PKCδ and tyrosine phosphorylation were inhibited by HSP25. Based on the above data, we suggest that HSP25 downregulates PKCδ, which is a key molecule for radiation-induced ROS generation and mitochondrial-mediated caspase-dependent apoptotic events.Oncogene (2005) 24, 3715–3725. doi:10.1038/sj.onc.1208440 Published online 4 April 2005
Lee Jin A,Lee Soon Min,Chung Sung-Hoon,Lee Jang Hoon,Shim Jae Won,Lim Jae Woo,Kim Chang-Ryul,Chang Yun Sil 대한의학회 2023 Journal of Korean medical science Vol.38 No.39
Background: In Korea, there have been no reports comparing the prevalence of major congenital anomalies with other countries and no reports on surgical treatment and longterm mortality. We investigated the prevalence of 67 major congenital anomalies in Korea and compared the prevalence with that of the European network of population-based registries for the epidemiological surveillance of congenital anomalies (EUROCAT). We also investigated the mortality and age at death, the proportion of preterm births, and the surgical rate for the 67 major congenital anomalies. Methods: Korean National Health Insurance claim data were obtained for neonates born in 2013–2014 and admitted within one-year-old. Sixty-seven major congenital anomalies were defined by medical diagnoses classified by International Classification of Diseases-10 codes according to the EUROCAT definition version 2014. Mortality and surgery were defined if any death or surgery claim code was confirmed until 2020. Poisson distribution was used to calculate the 95% confidence interval of the congenital anomaly prevalence. Results: The total prevalence of the 67 major anomalies was 433.5/10,000 livebirths. When compared with the prevalence of each major anomaly in EUROCAT, the prevalence of spina bifida, atrial septal defect (ASD), congenital megacolon, hip dislocation and/or dysplasia and skeletal dysplasia were more than five times higher in Korea. In contrast, the prevalence of aortic atresia/interrupted aortic arch and gastroschisis was less than one-fifth in Korea. The proportion of preterm births was 15.7%; however, more than 40% of infants with anencephaly, annular pancreas and gastroschisis were preterm infants. Additionally, 29.2% of the major anomalies were admitted to the neonatal intensive care units at birth, and 25.6% received surgical operation. The mortality rate was 1.7%, and 78.2% of the deaths occurred within the first year of life. However, in neonates with tricuspid valve atresia and stenosis, duodenal atresia or stenosis, and diaphragmatic hernia, more than half died within their first month of life. ASD and ventricular septal defect were the most common anomalies, and trisomy 18 and hypoplastic left heart syndrome were the most fatal anomalies. All infants with aortic atresia/interrupted aortic arch and conjoined twins received surgery. Conclusion: The proportion of surgeries, preterm births and mortality was high in infants with major congenital anomalies. The establishment of a national registry of congenital anomalies and systematic support by national medical policies are needed for infants with major congenital anomalies in Korea.